Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions

Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions

The CDC Advisory Committee on Immunization Practices (ACIP) recommended immunization with the recently licensed 13-valent pneumococcal conjugate vaccine (PCV13) for high-risk (immunocompromised) adults aged ≥19 years in 2012. This was in addition to the 23-valent pneumococcal polysaccharide vaccine...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Jeffrey Vietri, James Harnett, Birol Emir, Erica Chilson
Format:	Artykuł
Język:	English
Wydane:	Taylor & Francis Group 2020-01-01
Seria:	Human Vaccines & Immunotherapeutics
Hasła przedmiotowe:	13-valent pneumococcal vaccine pneumococcal conjugate vaccine pcv13 pneumococcal disease pneumococcal vaccines immunization risk factors
Dostęp online:	http://dx.doi.org/10.1080/21645515.2019.1632683

Podobne zapisy

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
od: Strutton David R, i wsp.
Wydane: (2012-08-01)

EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
od: M. V. Fedoseenko, i wsp.
Wydane: (2014-09-01)

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
od: Germaine Hanquet, i wsp.
Wydane: (2022-01-01)

Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
od: John M. McLaughlin, i wsp.
Wydane: (2019-04-01)

Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines
od: Hyunju Lee, i wsp.
Wydane: (2014-02-01)

Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children
od: Giske Biesbroek, i wsp.
Wydane: (2014-02-01)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
od: Kristiana Alexandrova Nikolova, i wsp.
Wydane: (2021-10-01)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
od: Mikkelsen Malene B, i wsp.
Wydane: (2023-08-01)

Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ
od: Starla Hayward, i wsp.
Wydane: (2016-04-01)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
od: George Gourzoulidis, i wsp.
Wydane: (2023-09-01)

Invasive pneumococcal disease in persons with predisposing factors is dominated by non-vaccine serotypes in Southwest Sweden
od: Karin Bergman, i wsp.
Wydane: (2021-08-01)

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered in a prime-boost regimen among Chinese infants: a randomized, double blind phase III clinical trial
od: Wenjuan Wang, i wsp.
Wydane: (2022-01-01)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
od: Thundon Ngamprasertchai, i wsp.
Wydane: (2023-06-01)

PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION
od: A. V. Rudakova, i wsp.
Wydane: (2014-01-01)

The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities
od: Yan Li, i wsp.
Wydane: (2021-11-01)

Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan
od: Ching-Fen Shen, i wsp.
Wydane: (2021-09-01)

Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study
od: Stephanie Perniciaro, i wsp.
Wydane: (2021-08-01)

Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea
od: Deborah Lehmann, i wsp.
Wydane: (2017-12-01)

Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany
od: Arijita Deb, i wsp.
Wydane: (2022-09-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
od: N. L. Chernaya, i wsp.
Wydane: (2012-02-01)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence
od: Erica Chilson, i wsp.
Wydane: (2020-11-01)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants
od: Sophie Warren, i wsp.
Wydane: (2023-08-01)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
od: Earnshaw Stephanie R, i wsp.
Wydane: (2012-04-01)

Results of immunoprophylaxis of HIV-infected patients with 13-valent conjugated pneumococcal vaccine
od: Alexander V. Zhestkov, i wsp.
Wydane: (2021-11-01)

Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands
od: Mirjam J. Knol, i wsp.
Wydane: (2015-11-01)

IAPSM’s Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in India
od: Chythra R. Rao, i wsp.
Wydane: (2024-12-01)

Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States
od: Johnna Perdrizet, i wsp.
Wydane: (2023-04-01)

Pharmacoeconomic aspects of vaccination against Pneumococcal Infection in Russia
od: A. V. Rudakova, i wsp.
Wydane: (2014-09-01)

EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE: EMERGING DATA FROM INVASIVE PNEUMOCOCCAL DISEASE, PNEUMONIA, ACUTE OTITIS MEDIA AND NASOPHARYNGEAL CARRIAGE
od: Ralf Rene Reinert, i wsp.
Wydane: (2012-06-01)

Streptococcus pneumoniae Serotype 12F-CC4846 and Invasive Pneumococcal Disease after Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Japan, 2015–2017
od: Satoshi Nakano, i wsp.
Wydane: (2020-11-01)

Comment on: ‘Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada’, Wilson et al., 22 June 2018
od: Ashleigh McGirr, i wsp.
Wydane: (2018-11-01)

Effect of different schedules of ten-valent pneumococcal conjugate vaccine on pneumococcal carriage in Vietnamese infants: results from a randomised controlled trialResearch in context
od: Heidi Smith-Vaughan, i wsp.
Wydane: (2023-03-01)

Analysis of 13-valent pneumococcal polysaccharide conjugate vaccine among children born in Hangzhou from 2017 to 2021
od: Xinren Che, i wsp.
Wydane: (2023-05-01)

Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis
od: Hannah M.Garcia Garrido, i wsp.
Wydane: (2020-12-01)

Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China
od: Yu Hu, i wsp.
Wydane: (2022-01-01)

Vaccine effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: a systematic search and meta-analysis
od: Melina Gade Sikjær, i wsp.
Wydane: (2023-01-01)

Increased Invasive Pneumococcal Disease, North East England, UK
od: Catherine Houseman, i wsp.
Wydane: (2017-01-01)

Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands
od: Michele Wilson, i wsp.
Wydane: (2023-06-01)

Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria
od: Sarah J. Pugh, i wsp.
Wydane: (2018-12-01)

Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects
od: Salil Bendre, i wsp.
Wydane: (2024-02-01)